Michael Davis, MD
Endocrinology, Diabetes & Metabolism · Mobile, ALNPI 1669429171
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 803 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations.
Across 803 payments — averaging $15.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Abbott$901
- Medtronic$861
- AstraZeneca$845
- Sanofi-aventis U.S. LLC$791
- plus $5K from 35 others
What the payments were for
- Food & beverage$12,123100%
- Education$440%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$145
How this compares
$12,168 in reported general payments places this provider in the 65th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 498 | $694,280 |
| MounjaroTirzepatide | 297 | $413,615 |
| JardianceEmpagliflozin | 156 | $212,543 |
| FarxigaDapagliflozin Propanediol | 200 | $184,754 |
| TrulicityDulaglutide | 134 | $168,315 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 142 | $112,565 |
| Tresiba Flextouch U-200Insulin Degludec | 77 | $92,134 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $78,306 |
| Tresiba Flextouch U-100Insulin Degludec | 115 | $69,956 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 73 | $64,310 |
| RybelsusSemaglutide | 47 | $57,459 |
| Humalog Kwikpen U-100Insulin Lispro | 166 | $52,239 |
| Novolog FlexpenInsulin Aspart | 173 | $51,798 |
| ForteoTeriparatide | 12 | $47,461 |
| Humulin R U-500Insulin Regular, Human | 17 | $44,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $2,279 | $796,259627 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Lyumjev | $1,870 | $654,640552 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $122 | $234,405182 claims |
| AstraZenecaFarxiga | $845 | $184,754200 claims |
| PfizerGenotropin | $31 | $37,25518 claims |
| AbbVieSynthroid | $220 | $35,011396 claims |
| Johnson & JohnsonInvokana | $68 | $33,04719 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $791 | $23,24457 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $116 | $18,2571,528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Mobile
- Wilburn BoltonMobile$52K
- Anita KemmerlyMobile$13K
- Heather FishelMobile$11K
- Michael GalitzMobile$10K
- Jocelyn HewittMobile$9K
- Huey McDanielMobile$8K
- Stephen DavisMobile$7K
- Ross del FierroMobile$6K
- Jessica BhathalMobile$6K
- Neil SchaffnerOpelika$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.